Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca's Lynparza Looks To Hang On To Lead, With Tesaro's Niraparib On The Way

Mar 14 2017

• By Emily Hayes

Cancer cells

Related Content

FDA defies advisers; OK's AZ's ovarian cancer drug Lynparza

Dec 20 2014

Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy

Oct 27 2016

Clovis Transitions To Commercial Stage On Rubraca Approval

Dec 20 2016

Related Companies

AstraZeneca PLC

Clovis Oncology, Inc.

Tesaro, Inc.

Clovis Oncology, Inc.

Additional Topics

Clinical Trials Regulation Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.